Ionis Pharmaceuticals, Inc. (IONS)
59.88
-0.48
(-0.80%)
USD |
NASDAQ |
Sep 01, 16:00
60.02
+0.14
(+0.23%)
After-Hours: 07:38
Ionis Pharmaceuticals Cash from Investing (Quarterly) : 23.50M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.50M |
| March 31, 2026 | 536.82M |
| December 31, 2025 | -419.50M |
| September 30, 2025 | 91.34M |
| June 30, 2025 | -120.07M |
| March 31, 2025 | 170.46M |
| December 31, 2024 | 68.21M |
| September 30, 2024 | -340.80M |
| June 30, 2024 | 62.45M |
| March 31, 2024 | 76.10M |
| December 31, 2023 | -26.71M |
| September 30, 2023 | 68.71M |
| June 30, 2023 | 69.52M |
| March 31, 2023 | -325.64M |
| December 31, 2022 | 212.15M |
| September 30, 2022 | -183.93M |
| June 30, 2022 | -3.304M |
| March 31, 2022 | -287.55M |
| December 31, 2021 | 95.11M |
| September 30, 2021 | 121.97M |
| June 30, 2021 | -101.03M |
| March 31, 2021 | 78.86M |
| December 31, 2020 | 274.48M |
| September 30, 2020 | 15.31M |
| June 30, 2020 | 79.70M |
| Date | Value |
|---|---|
| March 31, 2020 | -95.01M |
| December 31, 2019 | 138.19M |
| September 30, 2019 | 1.396M |
| June 30, 2019 | -110.69M |
| March 31, 2019 | -70.17M |
| December 31, 2018 | -326.21M |
| September 30, 2018 | -307.67M |
| June 30, 2018 | -375.17M |
| March 31, 2018 | 79.49M |
| December 31, 2017 | -54.21M |
| September 30, 2017 | -150.10M |
| June 30, 2017 | 14.70M |
| March 31, 2017 | -168.68M |
| December 31, 2016 | 20.80M |
| September 30, 2016 | -57.09M |
| June 30, 2016 | 53.46M |
| March 31, 2016 | 39.43M |
| December 31, 2015 | 27.96M |
| September 30, 2015 | -29.28M |
| June 30, 2015 | -95.39M |
| March 31, 2015 | 36.65M |
| December 31, 2014 | -50.79M |
| September 30, 2014 | -24.49M |
| June 30, 2014 | -32.39M |
| March 31, 2014 | 24.82M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Biogen, Inc. | -3.839B |
| BridgeBio Pharma, Inc. | 17.89M |
| Vertex Pharmaceuticals, Inc. | -45.80M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 565.53M |
| Cash from Financing (Quarterly) | -412.29M |
| Free Cash Flow | -567.50M |
| Free Cash Flow Per Share (Quarterly) | 3.309 |
| Free Cash Flow to Equity (Quarterly) | 967.92M |
| Free Cash Flow to Firm (Quarterly) | 569.67M |
| Free Cash Flow Yield | -5.81% |